Cladis Investment Advisory LLC Increases Position in Johnson & Johnson (NYSE:JNJ)

Cladis Investment Advisory LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 3.0% in the 3rd quarter, Holdings Channel reports. The fund owned 4,354 shares of the company’s stock after purchasing an additional 125 shares during the period. Cladis Investment Advisory LLC’s holdings in Johnson & Johnson were worth $706,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of JNJ. Lynx Investment Advisory acquired a new stake in shares of Johnson & Johnson in the second quarter worth approximately $210,000. Sage Capital Advisors llc grew its stake in shares of Johnson & Johnson by 0.7% during the 2nd quarter. Sage Capital Advisors llc now owns 42,785 shares of the company’s stock valued at $6,254,000 after buying an additional 292 shares during the period. Eastover Investment Advisors LLC raised its position in shares of Johnson & Johnson by 2.3% in the 2nd quarter. Eastover Investment Advisors LLC now owns 38,982 shares of the company’s stock worth $5,693,000 after buying an additional 878 shares during the period. Olistico Wealth LLC boosted its holdings in Johnson & Johnson by 2.9% in the second quarter. Olistico Wealth LLC now owns 3,584 shares of the company’s stock valued at $524,000 after acquiring an additional 100 shares during the last quarter. Finally, Kingswood Wealth Advisors LLC increased its stake in Johnson & Johnson by 32.4% during the second quarter. Kingswood Wealth Advisors LLC now owns 29,557 shares of the company’s stock worth $4,320,000 after acquiring an additional 7,227 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $155.01 on Monday. The firm has a market cap of $373.21 billion, a price-to-earnings ratio of 22.43, a PEG ratio of 2.75 and a beta of 0.53. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The business’s 50 day moving average is $159.15 and its two-hundred day moving average is $156.46. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.66 earnings per share. Analysts forecast that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.20%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Analysts Set New Price Targets

JNJ has been the subject of a number of research reports. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Guggenheim lifted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Citigroup increased their price target on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Finally, Morgan Stanley upped their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $175.67.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.